Mosseri Marlio Charles 4

What Happened
Charles Mosseri Marlio, reported as a 10% owner, purchased 50,000 shares of Nuvectis Pharma, Inc. (NVCT) in open-market transactions on 2026-06-30. The weighted average purchase price was $18.32 per share (range $18.29–$18.32), for an aggregate cost of approximately $916,000. The filing indicates these were multiple same-direction open-market buys executed through a broker-dealer and reported on a single line.

Key Details

• Transaction date: 2026-06-30 (Form 4 filed 2026-07-01). Filing appears timely.
• Price: Weighted avg $18.32; price range $18.29–$18.32 (see footnote).
• Shares purchased: 50,000; total value ≈ $916,000.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnotes: F1 — purchases aggregated on one line; reporting person can provide per-price breakdown on request. F2 — Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF (the reporting vehicle).
• Insider status: 10% beneficial owner (large shareholder), not reported as an executive officer in this filing.

Context
Open-market purchases by large shareholders can be seen as a straightforward buy signal (adds to stake) but do not disclose motivation. As a 10% owner, this represents institutional/large-holder activity rather than routine employee option exercises or grants. The filing does not indicate any sales, option exercises, or tax-withholding in connection with these transactions.